摘要
目的通过检测信号转导和转录激活因子-3(STAT3)、血管内皮生长因子(VEGF)、微血管密度(MVD)在良、恶性嗜铬细胞瘤中的表达情况,探讨STAT3、VEGF能否成为一种预判恶性嗜铬细胞瘤的指标和肿瘤治疗的潜在靶点。方法选取1986年10月至2006年8月住院经手术治疗、且有完整的临床、病理和随访资料的嗜铬细胞瘤患者存档石蜡标本38例,其中良性嗜铬细胞瘤(良性组)21例,恶性嗜铬细胞瘤(恶性组)17例。恶性组首次手术确诊为嗜铬细胞瘤后随访4～155个月,良性组首次手术确诊为嗜铬细胞瘤后随访69～240个月;采用免疫组织化学技术,检测良性组、恶性组中STAT3、VEGF和MVD的表达情况。结果 STAT3在恶性组中的阳性表达率为70.6%,明显高于良性组中的阳性表达率(23.8%),两组间STAT3的表达具有显著的统计学差异(P<0.05)。VEGF在恶性组中的阳性表达率为82.4%,明显高于良性组中的阳性表达率(23.8%),且表达具有统计学意义(P<0.05)。MVD在恶性组中的阳性表达为36.41±13.00,良性组中为21.43±8.05,两者之间有显著性统计学意义(P<0.05)。在嗜铬细胞瘤中,STAT3与VEGF的表达以及VEGF与MVD的表达均呈正相关。结论 STAT3和VEGF有望成为预判嗜铬细胞瘤良、恶性的一种指标,并且有望成为肿瘤治疗的潜在靶点。
Objective To explore the expressions of STAT3,VEGF,microvessel density （MVD） and their relationships in benign and malignant pheochromoeytoma,so as to discuss the potential role of STAT3 and VEGF as useful markers of malignant pheoehromoeytoma. Methods Data of 38 patients with pheoehromoeytoma from Oct. 1986 to Aug. 2006 were studied retrospectively. 21 cases were diagnosed as benign neoplasms and the others were malignant. The expressions of STAT3,VEGF and MVD were analyzed in all these cases with immunohistochemical method. The benign cases were followed up for 69 to 240 months,while the malignant cases 4 to 155 months. Results Both STAT3 and VEGF highly expressed in the malignant cases, but lowly expressed in the benign ones,with significant difference （P〈0. 05）. Moreover, the expression of MVD was higher in the malignant cases than in the benign cases, with significant difference （P〈0.05）. The expressions of STAT3 and VEGF were positively correlated with MVD. Conclusions STAT3 and VEGF in pheoehromocytoma contribute to tumor angiogenesis. The expressions of STAT3 and VEGF may play an important role as useful markers in the diagnosis of malignant pheochromoeytoma.
出处
《现代泌尿外科杂志》
CAS
2012年第5期439-442,共4页
Journal of Modern Urology
基金
上海市自然科学基金(No.09ZR1418500)
上海市教委科研创新项目(No.11YZ58)
